Neuraminidase surface proteins on the exterior of the influenza virus provide targets for newly discovered, broadly protective antibodies.

Friday, October 25, 2019 Broadly Protective Antibodies Could Lead to Better Flu Treatments and Vaccines Most flu vaccines work by teaching the immune system to attack hemagglutinin (HA) proteins on the surface of the flu virus. However, neuraminidase (NA) surface proteins could also be a good target for flu vaccines and treatments. NIAID-supported researchers have discovered three new antibodies which bind to influenza NA proteins. These antibodies appear to provide broad, robust protection against many different kinds of influenza when tested in mice, and they could provide the basis for better treatments or vaccines for influenza in people. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107